This document provides guidance for the validation, verification, calibration, quality assurance (QA), and quality control (QC) of automated multichannel hematology analyzers for manufacturers, end-user clinical laboratories, accrediting organizations, and regulatory bodies. In addition, end-user clinical laboratories will find guidance for establishment of clinically reportable intervals and for QA for preexamination and examination aspects of their systems.

A standard for global application developed through the Clinical and Laboratory Standards Institute consensus process.
The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI’s consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

Appeals Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeals, documented in the CLSI Standards Development Policies and Processes, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute
950 West Valley Road, Suite 2500
Wayne, PA 19087 USA
P: +1.610.688.0100
F: +1.610.688.0700
www.clsi.org
standard@clsi.org
Validation, Verification, and Quality Assurance of Automated Hematology Analyzers; Approved Standard—Second Edition

Volume 30 Number 14

Albert Rabinovitch, MD, PhD
Patrick Barnes
Krista M. Curcio, MT(ASCP)
John Dorman, MT(ASCP)
Albert Huisman, PhD
Lan Nguyen
Patrick O’Neil, BS, MLT

Abstract

Clinical and Laboratory Standards Institute document H26-A2—Validation, Verification, and Quality Assurance of Automated Hematology Analyzers; Approved Standard—Second Edition provides guidance for the validation, verification, calibration, quality assurance (QA), and quality control (QC) of automated multichannel hematology analyzers. The intended audience includes manufacturers of such devices, end-user clinical laboratories, accrediting organizations, and regulatory bodies.


The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org. If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: customerservice@clsi.org; Website: www.clsi.org.
Copyright ©2010 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to permissions@clsi.org.

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, e-mail permissions@clsi.org.

Suggested Citation


Previous Editions:
October 1989, December 1996, August 2009

Reaffirmed:
September 2016

ISBN 1-56238-728-6
ISSN 0273-3099
Contents

Abstract .................................................................................................................................................... i

Committee Membership ........................................................................................................................ iii

Foreword .............................................................................................................................................. vii

1 Scope .......................................................................................................................................... 1

2 Introduction ................................................................................................................................ 1

3 Standard Precautions .................................................................................................................. 1

4 Terminology ....................................................................................................................................
   4.1 A Note on Terminology ................................................................................................. 2
   4.2 Definitions ..................................................................................................................... 2
   4.3 Abbreviations and Acronyms ........................................................................................ 9

5 Validation (Manufacturer) ....................................................................................................... 10
   5.1 Objectives .................................................................................................................... 10
   5.2 Performance Specifications and Characteristics .......................................................... 11
   5.3 General Statistical Considerations ............................................................................. 11
   5.4 Study Specimens and Subject Protection .................................................................... 12
   5.5 Specifications Overview .............................................................................................. 16
   5.6 Calibration and Quality Control .................................................................................. 21
   5.7 Carryover ..................................................................................................................... 24
   5.8 Lower Limit of Detection and Lower Limit of Quantitation ....................................... 25
   5.9 Fresh Blood Short-Term Imprecision ........................................................................ 26
   5.10 Commercial Controls Repeatability and Within-Device Imprecision ......................... 27
   5.11 Comparability (Correlation) ........................................................................................ 27
   5.12 Analytical Measuring Interval ..................................................................................... 35
   5.13 Regulatory Considerations .......................................................................................... 35

6 Verification (End-User Laboratory) ........................................................................................ 36
   6.1 Background (Limit of Blank) ...................................................................................... 37
   6.2 Carryover ..................................................................................................................... 37
   6.3 Imprecision (Reproducibility) ...................................................................................... 37
   6.4 Lower Limits of Detection and Quantitation ................................................................ 37
   6.5 Analytical Measuring Interval ..................................................................................... 37
   6.6 Comparability (Correlation) ........................................................................................ 37
   6.7 Mode-to-Mode Comparability ..................................................................................... 38
   6.8 Interferences ................................................................................................................ 38
   6.9 Clinically Reportable Intervals .................................................................................... 38
   6.10 Reference Intervals ...................................................................................................... 39

7 Quality Assurance and Quality Control ................................................................................... 39
   7.1 Quality Assurance Manual .......................................................................................... 40
   7.2 Preexamination Variables ............................................................................................ 40
   7.3 Calibration ..................................................................................................................... 43
   7.4 Imprecision .................................................................................................................. 47
   7.5 Quantitative Quality Control ....................................................................................... 48
   7.6 Blood Film Morphology, Including White Blood Cell Differential ......................... 55
Contents (Continued)

7.7 Proficiency Testing .......................................................... 55
References ............................................................................. 57
Appendix A. Plasma Interferent Correction ............................. 65
Appendix B. Whole Blood Concentration and Dilution ............. 67
Appendix C. Calibrators ......................................................... 69
Appendix D. Within-Run Imprecision Data Recording ............. 73
Appendix E. Establishing Laboratory-Specific Quality Control Means and Ranges .................. 74
Summary of Delegate Comments and Working Group Responses .......... 76
The Quality Management System Approach .......................... 90
Related CLSI Reference Materials ........................................ 92
Foreword

From a medical perspective, the value of an automated hematology analyzer is to provide physicians and other health care providers with reliable hematology data for patient management. From a patient and regulatory perspective, all complete blood count (CBC) results should be statistically and medically comparable on any hematology analyzer.

Reliable data depend on robust system design, which is initially validated by the manufacturer using formal study protocols/procedures, and subsequently verified by the end-user laboratory. Manufacturers’ validations typically include a combination of in-house testing with normal donor blood specimens and evaluations of patient specimens at external practicing clinical laboratories. Verification should focus on the laboratory’s specific patient populations.

Because CBC analyses are performed on whole blood, which is a heterogeneous suspension of blood cells, particular attention to various preexamination aspects of specimen collection and handling is critical to success in generating accurate patient results.

With respect to end-user quality control (QC) in the examination phase, the needs of clinical chemistry established the original patterns of internal and external QC methodology and the design of control materials and calibrators. Although automated hematology analyzers share these principles, they also have unique characteristics that require some specialized approaches to QC.

This document replaces and expands on two CLSI hematology documents (H26-A and H38-P) that are no longer in the consensus process. Those documents addressed only calibration and QC of automated analyzers. The present new document adds comprehensive sections for system validation and verification, as well as consideration of preexamination topics. Its approach is more practical than the previous documents, and is focused on specific technical details, with greatly expanded literature references.

Key Words

Analytical measuring interval, automated hematology, carryover, clinically reportable interval, comparability, correlation, imprecision, limit of blank, lower limit of detection, lower limit of quantitation, quality control, reference intervals, repeatability, validation study design, verification study design
Validation, Verification, and Quality Assurance of Automated Hematology Analyzers; Approved Standard—Second Edition

1 Scope
This document covers portions of the life cycle of an automated multichannel hematology system and provides guidance for validation, verification, calibration, quality assurance (QA), and quality control (QC) through standardized approaches to ensure good laboratory science and clinical relevance. The intended audience includes manufacturers of such devices, end-user clinical laboratories, accrediting organizations, and regulatory bodies.

End-user clinical laboratories will also find guidance for establishment of clinically reportable intervals (CRIs) and for QA for preexamination and examination aspects of their systems.

Because current blood cell counters also provide results beyond particle counting and differential separation of cell types, such as expanded platelet and reticulocyte measurements, extended leukocyte differential subtyping, and most recently, proteomic measurements through antigenic identification (ID) using fluorescence measurements, consult the potentially relevant CLSI documents H42, H43, H44, H52, and I/LA24.

2 Introduction
Historically, each complete blood count (CBC) instrument/reagent manufacturer developed its unique approaches to system validation and performance claims. It is hoped that this document will provide better standardization and transparency across manufacturers. Similarly, a uniform approach to end-user laboratory verification was lacking, and this document should assist that audience in developing consistent testing.

Calibration, internal QC, and external quality assessment (EQA) of hematology analyzers are commonly dependent on stabilized blood products that may contain surrogate particles and nonhuman cells in a nonphysiological fluid. When possible, fresh human blood should be part of an overall QC program, to enhance linkage between QC data and reportable patient results.

In addition to the use of stabilized blood, data generated by statistical analyses of patient assays serve as sources of information for QC, as commonly practiced in the hematology section of the clinical laboratory.

3 Standard Precautions
Because it is often impossible to know what isolates or specimens might be infectious, all patient and laboratory specimens are treated as infectious and handled according to “standard precautions.” Standard precautions are guidelines that combine the major features of “universal precautions and body substance isolation” practices. Standard precautions cover the transmission of all known infectious agents and thus are more comprehensive than universal precautions, which are intended to apply only to transmission of blood-borne pathogens. Standard and universal precaution guidelines are available from the US Centers for Disease Control and Prevention. For specific precautions for preventing the laboratory transmission of all known infectious agents from laboratory instruments and materials and for recommendations for the management of exposure to all known infectious diseases, refer to CLSI document M29.
4 Terminology

4.1 A Note on Terminology

CLSI, as a global leader in standardization, is firmly committed to achieving global harmonization whenever possible. Harmonization is a process of recognizing, understanding, and explaining differences while taking steps to achieve worldwide uniformity. CLSI recognizes that medical conventions in the global metrological community have evolved differently in the United States, Europe, and elsewhere; that these differences are reflected in CLSI, International Organization for Standardization (ISO), and European Committee for Standardization (CEN) documents; and that legally required use of terms, regional usage, and different consensus timelines are all important considerations in the harmonization process. In light of this, CLSI’s consensus process for development and revision of standards and guidelines focuses on harmonization of terms to facilitate the global application of standards and guidelines.

To align the usage of terminology in this document with that of ISO, the term *accuracy*, in its metrological sense, refers to the closeness of the agreement between a measured quantity value and a true quantity value of a measurand, and comprises both random and systematic effects. *Trueness* is used in this document when referring to the closeness of agreement between the average of an infinite number of replicate measured quantity values and a reference quantity value; the measurement of trueness is usually expressed in terms of *bias*. *Precision* is defined as the “closeness of agreement between indications or measured quantity values obtained by replicate measurements on the same or similar objects under specified conditions.” As such, it cannot have a numerical value but may be determined qualitatively as high, medium, or low. For its numerical expression, the term *imprecision* is used, which is the “dispersion of results of measurements obtained under specified conditions.” In addition, different components of precision are defined in H26-A2, primarily *repeatability*, ie, “precision under conditions where independent test results are obtained with the same method on identical test items in the same laboratory by the same operator using the same equipment within short intervals of time,” whereas *reproducibility* describes “precision under conditions where test results are obtained with the same method on identical test items in different laboratories with different operators using different equipment.”

The term *measurand* (quantity intended to be measured [ISO/IEC Guide 99]), replaces the term *analyte* (component represented in the name of a measurable quantity) when its use relates to a biological fluid/matrix; and the term *measurement procedure* replaces the term *analytical method* for a detailed description of a measurement according to one or more principles and to a given method, based on a model and including any calculation to obtain a result.

The terms *preexamination*, *examination*, and *postexamination* were adopted in place of *preanalytical*, *analytical*, and *postanalytical*, and the term *sample* replaces the term *specimen* where appropriate.

All terms and definitions will be reviewed again for consistency with international use, and revised appropriately during the next scheduled revision of this document.

The users of H26-A2 should understand that the fundamental meanings of the terms are identical in many cases. The terms in this document are also consistent with those defined in the ISO 15189, ISO 17025, and ISO 9000 series of standards.

4.2 Definitions

**accuracy (measurement)** – closeness of agreement between a measured quantity value and a true quantity value of a measurand (ISO/IEC Guide 99).
The Quality Management System Approach

Clinical and Laboratory Standards Institute (CLSI) subscribes to a quality management system approach in the development of standards and guidelines, which facilitates project management; defines a document structure via a template; and provides a process to identify needed documents. The approach is based on the model presented in CLSI document HS01—A Quality Management System Model for Health Care. The quality management system approach applies a core set of “quality system essentials” (QSEs), basic to any organization, to all operations in any health care service’s path of workflow (ie, operational aspects that define how a particular product or service is provided). The QSEs provide the framework for delivery of any type of product or service, serving as a manager’s guide. The QSEs are:

- Documents and Records
- Equipment
- Information Management
- Process Improvement
- Organization
- Purchasing and Inventory
- Occurrence Management
- Customer Service
- Personnel
- Process Control
- Assessment—External and Internal
- Facilities and Safety

H26-A2 addresses the QSEs indicated by an “X.” For a description of the other documents listed in the grid, please refer to the Related CLSI Reference Materials section on the following page.

Adapted from CLSI document HS01—A Quality Management System Model for Health Care.
Path of Workflow

A path of workflow is the description of the necessary steps to deliver the particular product or service that the organization or entity provides. For example, CLSI document GP26—*Application of a Quality Management System Model for Laboratory Services* defines a clinical laboratory path of workflow, which consists of three sequential processes: preexamination, examination, and postexamination. All clinical laboratories follow these processes to deliver the laboratory’s services, namely quality laboratory information.

H26-A2 addresses the clinical laboratory path of workflow steps indicated by an “X.” For a description of the documents listed in the grid, please refer to the Related CLSI Reference Materials section on the following page.

<table>
<thead>
<tr>
<th>Preexamination</th>
<th>Examination</th>
<th>Postexamination</th>
</tr>
</thead>
<tbody>
<tr>
<td>Examination ordering</td>
<td>Sample collection</td>
<td>Sample transport</td>
</tr>
<tr>
<td>Sample receipt/processing</td>
<td>Examination</td>
<td>Results review and follow-up</td>
</tr>
<tr>
<td>Interpretaion</td>
<td>Results reporting and archiving</td>
<td>Sample management</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>C54</th>
<th>H03</th>
<th>H03</th>
<th>H03</th>
<th>X</th>
<th>X</th>
<th>C54</th>
<th>H03</th>
<th>H03</th>
<th>H03</th>
</tr>
</thead>
<tbody>
<tr>
<td>H04</td>
<td>H15</td>
<td>H07</td>
<td>H07</td>
<td>H07</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H42</td>
<td>H43</td>
<td>H42</td>
<td>H42</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H43</td>
<td>H43</td>
<td>H43</td>
<td>H43</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H44</td>
<td>H44</td>
<td>H44</td>
<td>H44</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Adapted from CLSI document HS01—*A Quality Management System Model for Health Care.*
Related CLSI Reference Materials


C54-A Verification of Comparability of Patient Results Within One Health Care System; Approved Guideline (2008). This document provides guidance on how to verify comparability of quantitative laboratory results for individual patients within a health care system.

EP05-A2 Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline—Second Edition (2004). This document provides guidance for designing an experiment to evaluate the precision performance of quantitative measurement methods; recommendations on comparing the resulting precision estimates with manufacturers’ precision performance claims and determining when such comparisons are valid; as well as manufacturers’ guidelines for establishing claims.


EP09-A2 Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline—Second Edition (2002). This document addresses procedures for determining the bias between two clinical methods, and the design of a method comparison experiment using split patient samples and data analysis.

EP15-A2 User Verification of Performance for Precision and Trueness; Approved Guideline—Second Edition (2005). This document describes the demonstration of method precision and trueness for clinical laboratory quantitative methods utilizing a protocol designed to be completed within five working days or less.

EP17-A Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline (2004). This document provides guidance for determining the lower limit of detection of clinical laboratory methods, for verifying claimed limits, and for the proper use and interpretation of the limits.

EP21-A Estimation of Total Analytical Error for Clinical Laboratory Methods; Approved Guideline (2003). This document provides manufacturers and end users with a means to estimate total analytical error for an assay. A data collection protocol and an analysis method that can be used to judge the clinical acceptability of new methods using patient specimens are included. These tools can also monitor an assay’s total analytical error by using quality control samples.

GP02-A5 Laboratory Documents: Development and Control; Approved Guideline—Fifth Edition (2006). This document provides guidance on development, review, approval, management, and use of policy, process, and procedure documents in the medical laboratory community.

GP27-A2 Using Proficiency Testing to Improve the Clinical Laboratory; Approved Guideline—Second Edition (2007). This guideline provides assistance to laboratories in using proficiency testing as a quality improvement tool.

* CLSI documents are continually reviewed and revised through the CLSI consensus process; therefore, readers should refer to the most current editions.
Related CLSI Reference Materials (Continued)


H04-A6  Procedures and Devices for the Collection of Diagnostic Capillary Blood Specimens; Approved Standard—Sixth Edition (2008). This document provides a technique for the collection of diagnostic capillary blood specimens, including recommendations for collection sites and specimen handling and identification. Specifications for disposable devices used to collect, process, and transfer diagnostic capillary blood specimens are also included.

H07-A3  Procedure for Determining Packed Cell Volume by the Microhematocrit Method; Approved Standard—Third Edition (2000). This document describes a standard microhematocrit method for determining packed cell volume; specifications for recommended materials and information on potential sources of error are also included.


H42-A2  Enumeration of Immunologically Defined Cell Populations by Flow Cytometry; Approved Guideline—Second Edition (2007). This document provides guidance for the immunophenotypic analysis of non-neoplastic lymphocytes by immunofluorescence-based flow cytometry; sample and instrument quality control; and precautions for acquisition of data from lymphocytes.

H43-A2  Clinical Flow Cytometric Analysis of Neoplastic Hematolymphoid Cells; Approved Guideline—Second Edition (2007). This document provides performance guidelines for the immunophenotypic analysis of neoplastic hematolymphoid cells using immunofluorescence-based flow cytometry; for sample and instrument quality control; and precautions for acquisition of data from neoplastic hematolymphoid cells.


H52-A  Fetal Red Cell Detection; Approved Guideline (2001). This document provides guidance for the quantitation of fetal red blood cells in blood and other biologic fluids. The performance characteristics of various flow cytometric and microscopic assays are reviewed, recommendations are made for control usage, and principles for distinction of F cells and fetal red cells are discussed.

I/LA24-A  Fluorescence Calibration and Quantitative Measurement of Fluorescence Intensity; Approved Guideline (2004). This guideline describes the basic principles, reference materials, and laboratory procedures upon which quantitative fluorescence calibration is based.

M29-A3  Protection of Laboratory Workers From Occupationally Acquired Infections; Approved Guideline—Third Edition (2005). Based on US regulations, this document provides guidance on the risk of transmission of infectious agents by aerosols, droplets, blood, and body substances in a laboratory setting; specific precautions for preventing the laboratory transmission of microbial infection from laboratory instruments and materials; and recommendations for the management of exposure to infectious agents.
Explore the Latest Offerings From CLSI!

As we continue to set the global standard for quality in laboratory testing, we are adding products and programs to bring even more value to our members and customers.

By becoming a CLSI member, your laboratory will join 1,600+ other influential organizations all working together to further CLSI’s efforts to improve health care outcomes. You can play an active role in raising global laboratory testing standards—in your laboratory, and around the world.

Find out which membership option is best for you at www.clsi.org/membership.

Find what your laboratory needs to succeed! CLSI U provides convenient, cost-effective continuing education and training resources to help you advance your professional development. We have a variety of easy-to-use, online educational resources that make eLearning stress-free and convenient for you and your staff.

See our current educational offerings at www.clsi.org/education.

When laboratory testing quality is critical, standards are needed and there is no time to waste. eCLIPSE™ Ultimate Access, our cloud-based online portal of the complete library of CLSI standards, makes it easy to quickly find the CLSI resources you need.

Learn more and purchase eCLIPSE at clsi.org/eCLIPSE.

For more information, visit www.clsi.org today.